Volume 11, Number 8—August 2005
Research
Cephalosporin-resistant Pneumococci and Sickle Cell Disease
Martha L. Miller*1, Caroline A. Obert*1, Geli Gao*, Najat C. Daw*, Patricia Flynn*, and Elaine Tuomanen*
Table 1
Distribution of β-lactam resistance in nasopharyngeal pneumococcal isolates from sickle cell disease patients
| Penicillin susceptibility* | No. isolates | Cefotaxime susceptibility* | No. isolates |
|---|---|---|---|
| Sensitive | 31 | Sensitive | 31 |
| Intermediate | 24 | Sensitive | 19 |
| Intermediate | 3 | ||
| Resistant | 2 | ||
| Resistant | 9 | Intermediate | 3 |
| Resistant | 6 |
*Definition of susceptibility per Clinical and Laboratory Standards Institute (formerly NCCLS) guidelines from 1994 and 1995 (10,11). Sensitive, penicillin V MIC<0.06 μg/mL, cefotaxime MIC<0.05 μg/mL; intermediate, penicillin V MIC 0.12–1 μg/mL, cefotaxime MIC 1 μg/mL; resistant, penicillin or cefotaxime MIC>2 μg/mL.
1These authors contributed equally to this study.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.